More on ELDN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.72 |
|
|||
| Open | $3.84 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $3.84 | ||||
| Day Low | $3.62 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 471,195 | ||||
- Rodman & Renshaw Starts Eledon Pharamceuticals (ELDN) at Buy
- NewcelX gets FDA feedback supporting NCEL-101 diabetes trial path
- NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
- Natera and Eledon partner on kidney transplant Phase 3 trial
- Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
- Form 8-K Eledon Pharmaceuticals, For: Jun 18
- Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink
- Eledon Pharamceuticals (ELDN) Reiterated at Overweight by Cantor Fitzgerald
- Eledon reports Phase 2 kidney transplant drug data at ATC
- Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit
Entities mentioned with ELDN
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
